



FOR IMMEDIATE RELEASE

CLC bio customized software supports Abcam's monoclonal development capability

Aarhus, Denmark and Cambridge, UK -- November 6, 2007 -- CLC bio, the premier bioinformatics solution provider, and Abcam, the world-leading research antibody supplier, today announced that CLC bio has met the first important milestone of the two companies' collaboration: the development of a customized epitope prediction software solution to augment Abcam's high through-put monoclonal antibody development programme.

Through automation of labor intensive manual workflows and by applying expert scientific knowledge, CLC bio's customized bioinformatics solution ensures a significant reduction in the time-to-market whilst ensuring that the antibodies are of the highest quality.

Dr Catherine Onley, Head of Product Development & Manufacture at Abcam, states: 'We searched the market to find the best bioinformatics solution provider for this highly specialized project and I am more than satisfied with CLC bio's performance. Their skilled IT developers and experienced bioinformatics scientists and project manager have developed an epitope prediction solution that exceeds our expectations. Abcam's in-house R&D programme will benefit significantly from this. I look forward to the next phase of our collaboration, where we will fully integrate the epitope prediction solution with our LIMS system.'

Dr Jannick D. Bendtsen, project manager and Senior Scientific Officer at CLC bio, said: 'We are very proud to help Abcam improve their R&D workflows and performance through this software consulting assignment. From a personal perspective, I'm thrilled to work on this Abcam project as it has been scientifically challenging. I look forward to seeing Abcam improve their competitive edge using this new bioinformatics solution.'

Parts of the epitope prediction functionalities will be included in future versions of CLC Protein Workbench and CLC Combined Workbench, which will facilitate epitope prediction in basic research. The unique Abcam-related work will be kept confidential between the two parties. The customized epitope prediction software follows CLC bio's concept of providing highly specialized bioinformatics solutions, based on a highly popular and well-proven platform. The Abcam solution is designed as a plug-in that is then fully integrated with the CLC Combined Workbench, CLC bio's premier desktop-based DNA, RNA, and protein sequence analysis and data management software.

Read more about CLC bio's customized software solutions on www.clcbioconsulting.com



About CLC bio

CLC bio is the world's leading full-service bioinformatics solution provider, solely focusing on the development of bioinformatics: software, hardware, data analysis, and custom-designed bioinformatics algorithms. CLC bio is an Apple solution provider and value added reseller.

CLC bio's mission is to be among the most innovative bioinformatics companies in the 21st century. This is realized through:

- Development of bioinformatics software and hardware based on the latest scientific findings
- User-friendly, integrated and intuitive cross-platform software solutions
- Continuous focus on customer needs and superior customer service
- Frequent product updates including the latest IT technologies and bioinformatics algorithms
- A flexible IT architecture, enabling customers to buy or develop individualized solutions at a reasonable price

About Abcam, Plc

Abcam plc is a producer and distributor of research-grade antibodies headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts, and a Japan office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial customers throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of approximately 35,000 products, most of which are antibodies, from over 200 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs 130 staff in its three operating companies.



Contact

For further information, please contact:

Dr. Catherine Onley, Head of Product Development & Manufacture

Abcam plc

332 Cambridge Science Park

Milton Road

Cambridge CB4 0FW

UK

Phone: +44 (0)1223 696000

E-mail: catherine.onley@abcam.com

Website: www.abcam.com

Thomas Knudsen, CEO

CLC bio

Gustav Wieds Vej 10

8000 Aarhus C

Denmark

Phone: +45 70 22 55 09

E-mail: info@clcbio.com

Website: www.clcbio.com